TheraRadar
Data updated: May 26, 2026

BALSALAZIDE DISODIUM

Immunology Approved 2007-12-28

Balsalazide disodium treats mildly to moderately active ulcerative colitis in adults and children five years of age and older. It helps patients manage active symptoms, though its use is typically limited to short-term periods of eight weeks for children and twelve weeks for adults. This medication is used to provide a local anti-inflammatory effect directly within the colon.

Source: FDA Label • Hikma

How BALSALAZIDE DISODIUM Works

This drug works by traveling intact to the colon, where it is broken down by bacteria to release mesalamine, the active therapeutic component. Once released, mesalamine provides a local anti-inflammatory effect on colonic cells, likely by blocking the production of specific metabolites that drive inflammation.

Source: FDA Label
4
Indications
--
Phase 3 Trials
18
Years on Market

Details

Status
Prescription
First Approved
2007-12-28
Routes
ORAL
Dosage Forms
CAPSULE, TABLET

BALSALAZIDE DISODIUM Approval History

2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
23 FDA actions from 2007 to 2025
Jun 2025 SUPPL
Label · Labeling
Apr 2025 ORIGINAL
Update
Feb 2024 SUPPL
Label · Labeling

What BALSALAZIDE DISODIUM Treats

1 indications

BALSALAZIDE DISODIUM is approved for 1 conditions since its original approval in 2007. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Ulcerative Colitis
Source: FDA Label

BALSALAZIDE DISODIUM Competitive Set

Pro

Three rings of competition based on shared molecular targets and treated indications.

Unlock 10 more competitors across all three rings.
Upgrade to Pro

Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.

Drugs Similar to BALSALAZIDE DISODIUM

3 of 20

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

ABRILADA
ADALIMUMAB-AFZB
1 shared
Pfizer
Shared indications:
AMJEVITA
ADALIMUMAB-ATTO
1 shared
Amgen
Shared indications:
APRISO
MESALAMINE
1 shared
SALIX
Shared indications:
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

BALSALAZIDE DISODIUM FDA Label Details

Indications & Usage

BALSALAZIDE DISODIUM is indicated for the treatment of Ulcerative Colitis.

Looking for the branded version?

COLAZAL

Full clinical data, patents, trials, and competitive landscape for balsalazide disodium.

See COLAZAL

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.